Skip to main content
. 2025 Jul 30;14(15):5381. doi: 10.3390/jcm14155381

Table A3.

COVID-19 severity in relation to demographics, comorbidities, days in hospital, max needs of FiO2% and outcome.

Characteristics Mild/Moderate
(N = 36)
Severe/Critical
(N = 475)
p-Value
Age 65.5 [37.0, 95.0] 68.0 [22.0, 99.0] 0.865 MW
Gender
 Male 9 (25.0%) 255 (53.7%) 0.00165 x2
 Female 27 (75.0%) 220 (46.3%)
FiO2
 Mean (SD) 22.3% (2.7%) 50.8% (22.8%) <0.001 MW
 Median [Min, Max] 21% [21%, 28%] 40% [21%, 100%]
Comorbidities
 CVS disease 11 (30.6%) 121 (25.5%) 0.635 x2
 Arterial hypertension 7 (19.4%) 208 (43.8%) 0.00742 x2
 Diabetes Mellitus 4 (11.1%) 93 (19.6%) 0.304 x2
 Malignancy 5 (13.9%) 37 (7.8%) 0.204 fx
 Immunosuppression 0 (0%) 8 (1.7%) 1 fx
 COPD 1 (2.8%) 38 (8.0%) 0.508 fx
 Sleep Apnea 0 (0%) 6 (1.3%) 1 fx
 Bronchial Asthma 0 (0%) 23 (4.8%) 0.395 fx
 Chronic kidney Disease 0 (0%) 5 (1.1%) 1 fx
 Neurological Disease 12 (33.3%) 74 (15.6%) 0.0119 x2
 Psychiatric Disease 12 (33.3%) 51 (10.7%) <0.001 fx
 Morbid obesity 0 (0%) 12 (2.5%) 1 fx
 Autoimmune Disease 2 (5.6%) 7 (1.5%) 0.127 fx
ECOG 4 0 (0%) 17 (3.6%) 0.623 fx
Days in hospital 14.5 [6.00, 48.0] 15.0 [5.00, 72.0] 0.646 MW
Outcome
 Improvement 36 (100%) 390 (82.1%) 0.0148 fx
 Death 0 (0%) 74 (15.6%)
 Discharge with O2 support 0 (0%) 6 (1.3%)
  Death 0 (0%) 74 (15.6%) 0.0197 x2

MW: Mann–Whitney U test, fx: Fisher exact test, x2: χ2 test.